Law firm welcomes partner to Bristol office
Law firm Osborne Clarke continues to strengthen its life sciences and healthcare and tech teams with the appointment of Mathilda Davidson, a transactional IP partner.
She joins the firm’s Bristol commercial team.
Davidson has spent her career to date at Gowling WLG, having made legal director in 2019, she also qualified at their legacy firm Wragge & Co in 2010.
A transactional IP specialist, she advises clients on research and development, and collaboration and licensing projects in the Life Sciences sector, as well as advising other technology-led businesses.
She advises companies and research institutions on product development and acquisition, collaboration and licensing deals, and brings extensive sector experience working with high-profile companies including AstraZeneca, Cancer Research Horizons (formerly Cancer Research Technology), Nxera Pharma (formerly Sosei Heptares), Oxford BioTherapeutics and Amphista Therapeutics.
Will James, partner and head of Osborne Clarke’s International Life Sciences and Healthcare Sector, said: “Mathilda brings fantastic experience and impressive industry-focused skills, which will complement the great work the firm is doing in the Life Sciences and Healthcare Sector. Her expertise will be a great fit to help grow our VC and spin-out work, while supporting our global biopharma client base on commercial and transactional work.”
Davidson said: “Osborne Clarke’s platform and support are very attractive, and I look forward to being a part of such a forward-thinking and dynamic law firm for this exciting next step in my career.”
